2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) elicits a broad spectrum of species-specific effects that have not yet been fully characterized. This study compares the temporal effects of TCDD on hepatic aqueous and lipid metabolite extracts from immature ovariectomized C57BL/6 mice and Sprague-Dawley rats using gas chromatography-mass spectrometry and nuclear magnetic resonance-based metabolomic approaches and integrates published gene expression data to identify species-specific pathways affected by treatment. TCDD elicited metabolite and gene expression changes associated with lipid metabolism and transport, choline metabolism, bile acid metabolism, glycolysis, and glycerophospholipid metabolism. Lipid metabolism is altered in mice resulting in increased hepatic triacylglycerol as well as mono-and polyunsaturated fatty acid (FA) levels. Mouse-specific changes included the induction of CD36 and other cell surface receptors as well as lipases-and FA-binding proteins consistent with hepatic triglyceride and FA accumulation. In contrast, there was minimal hepatic fat accumulation in rats and decreased CD36 expression. However, choline metabolism was altered in rats, as indicated by decreases in betaine and increases in phosphocholine with the concomitant induction of betaine-homocysteine methyltransferase and choline kinase gene expression. Results from these studies show that aryl hydrocarbon receptor-mediated differential gene expression could be linked to metabolite changes and species-specific alterations of biochemical pathways.
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2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a persistent environmental contaminant that elicits a broad spectrum of biochemical and toxic effects in a species-specific manner. These effects include hepatotoxicity, immunotoxicity, endocrine disruption, wasting syndrome, and lethality (Poland and Knutson, 1982) . The aryl hydrocarbon receptor (AhR), a ligand activated transcription factor in the basic helix-loop-helix-PerArnt-Sim (bHLH-PAS) family, has been shown to mediate the toxic effects of TCDD (Denison and Heath-Pagliuso, 1998; Gonzalez and Fernandez-Salguero, 1998; Poland and Knutson, 1982; Vorderstrasse et al., 2001) . Briefly, following ligand binding, the cytoplasmic TCDD:AhR complex translocates to the nucleus to form a heterodimer with the AhR nuclear translocator (ARNT), another bHLH-PAS family member. This heterodimer binds to dioxin response elements (DREs) in the regulatory regions of target genes causing altered gene expression (Denison et al., 2002; Hankinson, 1995) .
The conservation of AhR/ARNT signaling in mediating the toxic and biochemical effects of TCDD is well established (Gonzalez and Fernandez-Salguero, 1998; Mason and Safe, 1986; McGregor et al., 1998; Okey et al., 1989; Peters et al., 1999; Vorderstrasse et al., 2001) . AhR and ARNT share greater than 87% amino acid similarity across human, mouse, and rat species. Despite their conserved structure, function, and mechanism of action, there are significant qualitative and quantitative differences in response to TCDD, even between closely related species, such as humans, mice, and rats (Boverhof et al., 2006a; Dere et al., 2006 Dere et al., , 2011a Fletcher et al., 2005; Forgacs et al., forthcoming; Sato et al., 2008) . This study integrates comparative metabolomic and gene expression data to identify biochemical pathway perturbations that can be phenotypically anchored to TCDD-elicited hepatic responses in the mouse and rat.
Species-specific differences in histopathology, clinical chemistry, and global gene expression have previously been reported (Boutros et al., 2008; Boverhof et al., 2006a) . TCDD increased relative liver weight (RLW) in mice and rats due to different phenotypic responses. RLW increases are due to fatty accumulation in mice, whereas increases in rats are attributed to hypertrophy (Boverhof et al., 2006a) . Comparative genomewide gene expression studies also report differences in the number and identity of differentially expressed genes in response to TCDD, despite conserved induction of the AhR battery (Boverhof et al., 2006a; Dere et al., 2011b,c; Forgacs et al., forthcoming) . Furthermore, several orthologs are divergently regulated between species (i.e., same gene induced in one species and repressed in the other). Human HepG2, mouse Hepa1c1c7, and rat H4IIE cells as well as human, mouse, and rat primary hepatocytes also exhibit TCDD-elicited species-specific and divergent gene expression (Dere et al., 2011c; Forgacs et al., forthcoming) . These results are consistent with computational DRE searches in the human, mouse, and rat genomes, which found DRE distributions (i.e., location and number) are not conserved (Dere et al., 2011a; Sun et al., 2004) .
To further characterize species-specific AhR-mediated responses, nuclear magnetic resonance (NMR)-and gas chromatography-mass spectrometry (GC-MS)-based approaches were used to examine the aqueous and lipid profiles in hepatic extracts from immature ovariectomized (ovx) C57BL/6 mice and Sprague-Dawley rats. The current study used the same model, treatment regimen, and study design as our previous studies to leverage published histopathology, clinical chemistry, tissue level, and hepatic gene expression data (Boverhof et al., 2005 (Boverhof et al., , 2006a Kopec et al., 2008 Kopec et al., , 2010 in order to extend our comparative analyses and further elucidate pathways affected by TCDD. Published microarray gene expression data sets (Boverhof et al., 2006a; Dere et al., 2011a) and mouse GC-MS data (Kopec et al., 2010) were complemented with GC-MS analysis of rat hepatic extracts, as well as Comparative analysis and integration of gene expression with metabolomic data identified novel species-specific hepatic effects elicited by TCDD. Principal component analysis (PCA) identified differences in spectral profiles based on treatment, exposure time, and species. NMR peaks that significantly contributed to treatment or species differences were identified by comparison with libraries of known compounds and quantified. GC-MS analyses determined the relative quantity of specific hepatic fatty acids (FA) to further characterize TCDD-elicited changes in hepatic FA composition in both species. Finally, published whole-genome microarray data sets were integrated to identify TCDD-mediated gene expression changes that could be associated with the metabolomic and lipidomic effects. The integration of these studies provides additional compelling evidence of species-specific responses based on species-specific AhR-mediated differential gene expression and metabolomic profiles.
MATERIALS AND METHODS
Animal handling and treatment. Immature female Sprague-Dawley rats and C57BL/6 mice with body weights (BW) within 10% of the average BW were ovariectomized by the vendor (Charles River Laboratories, Wilmington, MA) on postnatal day (PND) 20 and received on PND 25. Immature animals are more sensitive to TCDD. Ovariectomy was included to minimize the effects of circulating estrogens. These models have been previously used to investigate TCDD effects on serum clinical chemistry, hepatic gene expression, and histopathology (Boverhof et al., 2005 (Boverhof et al., , 2006a Kopec et al., 2008 Kopec et al., , 2010 and therefore were used in this study to facilitate data integration (Boverhof et al., 2006b; Matthews et al., 2005; Poland and Knutson, 1982) . Animals were housed in polycarbonate cages containing cellulose fiber chips (Aspen Chip Laboratory Bedding, Northeastern Products, Warrensberg, NY) in a 23°C HEPA-filtered environment with 30-40% humidity and a 12-h light/dark cycle (0700 h-1900 h). Animals were allowed free access to deionized water and Harlan Teklad 22/5 Rodent Diet 8640 (Madison, WI) and acclimatized prior to dosing. At PND 28, animals were weighed, and a stock solution of TCDD (provided by the Dow Chemical Company, Midland, MI) was diluted in sesame oil (Sigma, St Louis, MO) to deliver (by oral gavage) 10 lg/kg for rats and 30 lg/kg for mice in 0.1 ml based on the average BW. Previous studies have demonstrated that 10 and 30 lg/kg TCDD for rats and mice, respectively, elicit comparable hepatic levels and hepatic effects in the absence of overt toxicity while inducing Cyp1a1 messenger RNA induction (Boverhof et al., 2005) . All treatments were staggered to ensure exposure was within 5% of the desired duration. Animals (n ¼ 5 per group) were sacrificed by cervical dislocation at 24, 72, 120, or 168 h postdose, and tissue samples were removed, weighed, flash frozen in liquid nitrogen, and stored at À80°C until further use. Liver samples (~0.5 g for mice and rats) were shipped (overnight) on dry ice to Wright State University for NMR analyses. All procedures were performed with the approval of the Michigan State University All-University Committee on Animal Use and Care.
RNA isolation. Hepatic tissue (~100 mg of the left lobe) obtained from previous studies (Boverhof et al., 2005) was retrieved from À80°C storage, and RNA was isolated using TRIzol Reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol with an added phenol:chloroform (Sigma) extraction. RNA samples were resuspended and stored in RNA storage solution (Ambion Inc., Austin, TX). RNA was quantified spectrophotometrically, and quality was confirmed by A260/A280 ratio as well as by agarose gel electrophoresis.
Microarray gene expression. The microarray study design and methodology for analysis of differential gene expression were described previously (Boverhof et al., 2005 (Boverhof et al., , 2006a . Only a subset of these microarray data is presented here for comparison with the metabolomics analyses. The complete rat data sets evaluated for comparison with metabolomic data were a custom complementary DNA (cDNA) and Affymetrix microarrays that were previously published (Boverhof et al., 2006a) . The complete mouse Agilent microarray was published by Dere et al. (2011a) . The custom rat cDNA array consisted of 8567 features representing 3022 unique genes (Unigene build number 48), the rat Affymetrix microarray (Rat Genome U34A chip) consisted of 8799 features representing 4859 unique genes, and the mouse Agilent array consisted of over 41,000 features representing 20,696 unique genes. These data sets were mined for genes selected to complement specific metabolic pathways identified from the NMR metabolomic and GC-MS data. Filtering criteria of an absolute fold change greater than 1.5 were applied. Statistical cutoffs for P1(t), empirical Bayes-derived posterior probabilities values obtained from model-based t values (Eckel et al., 2004) , greater than 0.9 were also applied to identify significant gene expression changes. The same fold change and P1(t) values were applied to all data sets and are available in Supplementary tables S1 and S2 for mouse and rat, respectively. Previous studies have verified microarray data by qRT-PCR for selected genes (Boverhof et al., 2005 (Boverhof et al., , 2006a Dere et al., 2011a) . In this study, additional genes associated with pathways of interest were also confirmed by qRT-PCR.
Quantitative real-time PCR. Selected gene expression profiles identified from microarray studies were verified by qRT-PCR as described previously (Boverhof et al., 2005 (Boverhof et al., , 2006a Kopec et al., 2008 Kopec et al., , 2010 N'Jai et al., 2008) . Briefly, cDNA was synthesized from total RNA by SuperScript II reverse transcriptase using an anchored oligo-dT primer as described by the manufacturer (Invitrogen). The cDNA was then used as a template in 30 ll PCR reactions consisting of 0.1lM of forward and reverse gene-specific primers, 3mM MgCl 2 , 1mM dNTPs, 0.025 IU AmpliTaq Gold DNA 42 FORGACS ET AL. polymerase, and 13 SYBR Green PCR buffer (Applied Biosystems, Foster City, CA). Gene names, accession numbers, forward and reverse primer sequences, and amplicon sizes are provided in Supplementary table S3. An ABI PRISM 7000 Sequence Detection System (Applied Biosystems) was used for PCR amplification and cDNA quantification. Copy number was determined using the standard curve approach with standardization to housekeeping genes to control for differences in RNA loading, quality, and cDNA synthesis (Vandesompele et al., 2002) . Statistical analysis was performed using SAS v9.1 (SAS Institute, Cary NC). Data were analyzed using ANOVA followed by Tukey's post hoc test. Differences between groups were considered significant at p < 0.05.
Gas chromatography-mass spectrometry. Mouse GC-MS evaluation was obtained from a published data set (Kopec et al., 2010) ; rat liver samples were extracted and evaluated in the current study using the same study design. Briefly, FAs were analyzed as their methyl esters by GC-MS after organic lipid extraction, acid hydrolysis, organic extraction, and methylation with methanolic HCl. Liver samples (~100 mg) were homogenized (Polytron PT2100; Kinematica AG, Luzern, CH) in 40% methanol. Homogenates were acidified with concentrated HCl, and lipids were extracted with chloroform:methanol (2:1) containing 1mM 2,6-di-tert-butyl-4-methylphenol (BHT; Sigma). Extraction efficiency controls (19:1n9 FA and 19:0 triacylglycerol; Nu-Chek Prep, Elysian, MN) were added, and the protein and aqueous phases were reextracted with chloroform. Organic phases were pooled, and a derivatization standard (19:2n6 free FA; Nu-Chek Prep) was added. Samples were dried under nitrogen, resuspended in 2% nonaqueous methanolic HCl, and incubated at 60°C overnight. Upon cooling to room temperature, 0.9% (wt/vol) NaCl and hexane were added, and the organic phase was collected. A loading control (17:1n9 FA methyl ester; Nu-Check Prep) was added, and samples were dried under nitrogen and resuspended in equal volumes of hexane. Separation was conducted on an Agilent 6890N GC interfaced to an Agilent 5973 mass spectrometer with a DB23 column (30-m length, 0.25-mm internal diameter, 0.25-lm film thickness). The temperature program consisted of 50°C-150°C at 40°C/min, 150°C-185°C at 5°C/min, 185°C-235°C at 3°C/min, and 235°C-250°C at 10°C/min. Data analysis was carried out using MassLynx software (v4.0; Waters Corporation) and reported as fold change of treated relative to controls of the calculated integration of peak areas for each respective FA species. Statistical analysis was performed using SAS v9.1 (SAS Institute). Data were analyzed using ANOVA followed by Tukey's post hoc test; significance was assessed as p < 0.05 for treatment effect per FA species at 24, 72, or 168 h, respectively. NMR spectroscopy. Extracts were prepared using a dual phase extraction procedure that allows for both the aqueous and the lipid fractions to be recovered simultaneously (Tyagi et al., 1996) . Briefly, individual livers were homogenized on ice using a 40 ml glass tissue homogenizer in methanol (MeOH), then chloroform, and then water to a final composition of MeOH:CHCl 3 :H 2 O (1:1:1 vol/vol/vol, 21 ml/g of liver). Homogenate was centrifuged (2000 3 g for 25 min) to facilitate separation into two phases and a pellet. The sample was transferred through filter paper into a separatory funnel, and the pellet was washed three times with the extracting solvent. The solution was left to stand at 4°C for 17-24 h to allow for phase separation. The upper aqueous phase was aspirated, partially evaporated under N 2 gas to remove MeOH, and lyophilized to dryness. The lower lipid-containing phase was isolated and dried down using N 2 gas, weighed to obtain total lipid content, and reconstituted in deuterocholorform (CDCl 3 ) for storage at À20°C. Dried aqueous extracts were reconstituted in 2 ml of H 2 O and treated with a Chelex 100 to remove divalent cations. The Chelex was removed via centrifugation, and the sample was lyophilized to dryness. The dried extract was reconstituted in deuterium oxide (D 2 O, 99.99%) and transferred into a 5 mm NMR tube. Trimethylsilylpropionic (2,2,3,3,d 4 C spectra (with nuclear Overhauser enhancement) were acquired from liver lipid extracts at a sample temperature of 293 K. Data acquisition parameters for 31 P included a 90°pulse, 645 Hz spectral bandwidth, 1.6 s acquisition time, 10.6 s interpulse delay (full T 1 relaxation), and approximately 2.25 h of signal averaging.
13
C spectra were acquired using a 70°pulse, 35 kHz spectral bandwidth, 1.3 s acquisition time, 1.9 s interpulse delay, and approximately 15 h of signal averaging. Aqueous liver extracts were analyzed using 1 H and proton-decoupled 31 P NMR at a sample temperature of 298 K. For 1 H NMR, a 2 s preacquisition saturation pulse was used to suppress the residual water signal, followed by a 90°observe pulse, 4.0 s acquisition time, and 7.0 s interpulse delay (data were signal averaged~45 min). Acquisition parameters for 31 P NMR included a 60°pulse, 1.6 s acquisition time, 3.6 s interpulse delay, and 20 h of signal averaging.
NMR data were processed on a Sun Microsystems computer using VNMR v6.1 software (Varian, Inc., Houston, TX). All 31 P NMR data were processed using exponential multiplication (yielding line broadening of 0.3 Hz for 1 H, 0.5 Hz for 13 C, and 1.0 Hz for 31 P), Fourier transformation, and baseline flattening (fifth order polynomial and spline correction). Two sequential approaches were used to analyze differences in NMR spectral data between experimental groups. A semiquantitative metabolomics approach was used to screen the data for features (spectral peaks) that were observed to change substantially with treatment and/or between time points. Then spectral peak integration of specific resonances provided quantitative results for metabolites of interest. Our metabolomics-based procedure did not incorporate any statistical testing. Rather, it was used to screen for NMR signals of potential interest, which were then quantified with applied significance testing. Comparisons of metabolite absolute concentrations (in lmol/g tissue) were performed using JMP statistical software (SAS, Inc.). Data homoscedasticity was checked using the Levine test (alpha ¼ 0.05). Homoscedastic data were analyzed by two-way ANOVA for each species separately, using treatment (vehicle control and TCDD treated) and time (72, 120, and 168 h) as factors. This test yielded an overall p value for the ANOVA model and additional p values for each factor (treatment and time) and effects due to ''treatment 3 time.'' Data that were statistically significant in the ANOVA model at the level of p 0.05 were further analyzed using a Tukey honestly significant difference post hoc test. Nonhomoscedastic data were analyzed using the Welch test (p 0.05).
Semiquantitative metabolomics screening. An integrated screening methodology for NMR spectral analysis, similar to that described previously (Jahns et al., 2009) , was extended to examine spectra from multiple nuclides simultaneously. It is based upon successive steps of feature extraction, data fusion, modeled-variance standardization, PCA, and feature-change estimation.
The objective was to screen spectra for salient features (intensity changes) that represent changes due to experimental conditions (TCDD or time posttreatment). These features were then further investigated using a targeted quantitative analysis. Briefly, the first step extracts single spectral features (peaks) characterized by mean amplitudes (equivalent to ''intelligent binning''). This results in a matrix of feature amplitudes for each sample (aqueous and lipid) and nuclear ( 1 H, 31 P, and 13 C) spectral type. Each animal provided four feature matrices ( 1 H-aqueous, 31 P-aqeuous, 13 C-lipid, and 31 P-lipid) that were fused into a single matrix. Feature amplitudes were scaled to the SD of a reference group (data standardization), and PCA was performed on the standardized feature matrix. Group centroids were estimated in PCA space from five or six principal components, and the contribution each original feature COMPARATIVE METABOLOMIC AND GENOMIC ANALYSES 43 Downloaded from https://academic.oup.com/toxsci/article-abstract/125/1/41/1667838 by guest on 01 February 2019 made to the centroids was calculated. Differences between two feature centroid values for any binary combination of groups provides a feature-change estimate, which was used to identify features exhibiting a significant change between groups of interest (e.g., treated vs. control at a specific time). This methodology provided an integrated examination of all four spectral types to identify salient spectral features for subsequent quantitative analysis.
Quantification of specific metabolite NMR resonances. Specific lipid resonances were identified in the 13 C spectra for triacylglycerides (TAG), cholesterol/cholesterol esters, phosphatidylcholine (PtdC), n3-fatty acids (n3-FA), and n6-fatty acids (n6-FA) based upon NMR chemical shift assignments (Sillerud et al., 1986; Halliday et al., 1988) and measurements of lipid standards. For TAG, the C1 and C3 carbons from the glycerol moiety at 62.7 ppm (magnetically equivalent resonances) was used for quantification. For cholesterol/cholesterol esters, the C18 carbon at 12.2 ppm was chosen for quantification. The methyl carbon resonance from the choline headgroup of PtdC, (CH 3 ) 3 N-, at 54.6 ppm provided a measure of PtdC. The n3-FA and n6-FA can each be represented by several NMR signals within a narrow range of ppm. The n2 carbon from all species of n3-FA provides a unique resonance(s) within the range 20.99-21.03 ppm, whereas the n3 carbon of n6-FA yields a distinct resonance(s) within the range 32.03-32.29 ppm. The slight shift of these carbon signals within the given range arises from different carbon chain lengths of these FAs. Thus, signal intensities were integrated over the entire range of chemical shifts for these unique signals to quantify lipid species.
The 13 C metabolite signals were quantified by peak integration relative to the known concentration of CDCl 3 solvent, after correction for T 1 saturation and nuclear Overhauser effect (NOE). This correction involved acquiring data under fully relaxed acquisition conditions for a representative sample (5 T 1 s without NOE; interpulse delay of 250 s). The ratio of the intensity of a peak of interest (e.g., cholesterol) to the intensity of the solvent signal (CDCl 3 ) was then calculated for fully relaxed (R fr ) and partially saturated (R ps ) spectra. Saturation factors were determined by calculating the (R fr /R ps ) ratio for each peak of interest. For the n3-FA and n6-FA signals, which required integration of several overlapping resonances within a range of parts per million, we measured an ''apparent'' saturation factor representing all signals encompassed in the designated chemical shift range. This approach may introduce a minimal error, but it is reasonable to assume that the carbon signals within the designated parts per million range have very similar T 1 and NOE because they represent the same carbon atom types (i.e., n2 carbon of n3-FA; n3 carbon of n6-FA). Thus, we expect that this error is negligible, and measured changes in signal intensity directly reflect a change in pool size for these classes of FAs. 31 P-lipid spectra were fit by Lorentzian lineshape analysis and quantified based on the PtdC signal intensity, which was quantified from the 13 C spectrum as described. Because these spectra were acquired under fully relaxed conditions, no correction for T 1 saturation was necessary. The 31 P and 1 H spectra of aqueous extracts, however, required correction for T 1 saturation (and NOE in the case of 31 P), which was done as described above for 13 C NMR of lipid samples. All metabolite concentrations were normalized to liver weight and are reported as lmol/g tissue.
RESULTS
Qualitative Metabolomic Analyses NMR spectra of lipid ( 13 C and 31 P) and aqueous ( 1 H and 31 P) hepatic extracts from treated and control animals were evaluated by PCA with species-, time-, and treatment-dependent separation visualized on a three-dimensional plot (Fig. 1) . Principal component (PC) 1, PC2, and PC3 represent 58% of the total data covariance. Separation along PC1 indicates treatmentdependent differences in both species. Although time-dependent separation is not obvious in the first three PCs, inclusion of PC5 and PC6 (80% and 83% of the data covariance, respectively) indicate temporal effects also contributed to separation (data not shown). Time-dependent effects were largely associated with treatment effects and not a significant factor when considered independently. Consequently, our subsequent analyses focused on treatment effects in both species.
NMR spectra were used to screen hepatic extracts for potential ''spectral features'' (i.e., metabolite signals) that showed differences in intensity between groups. The four fused NMR data sets ( 1 H and 31 P spectra for aqueous metabolites, 13 C and 31 P spectra for lipids) comprised 336 spectral features per species. Combining the NMR data sets enabled direct comparisons of features from different spectra, leading to the quantitative analysis of 22 independent signals showing treatment effects. Some spectral features were highly complex with multiple overlapping signals that could not be assigned to specific metabolites. Assigned signals were further analyzed to examine quantitative changes in metabolite levels elicited by TCDD.
Mouse and rat NMR spectra were analyzed quantitatively for TCDD-elicited changes in specific metabolite signals (Tables 1  and 2 ; Supplementary tables S4 and S5).
13 C spectra provided measures of cholesterol, TAG, and various FAs, whereas 31 P NMR spectra of the same extracts assessed major phospholipids including phosphatidylcholine (PtdC), phosphatidylserine (PtdS), phosphatidylethanolamine (PtdE), phosphatidylinositol (PtdI), cardiolipin, and sphingomyelin (SM). Aqueous extracts were also evaluated by 31 P NMR for phosphomonoesters and phosphodiesters and in the 1 H NMR spectra to identify various small molecule metabolites including acetate, lactate, pyruvate, and phosphocholine (Pcho). Overall, the list of salient spectral features was more extensive in mice compared with rats. In mice, the dominant features showing increased intensity in TCDD-treated samples relative to vehicle controls were in the 13 C spectra representing TAG at 62.8 and 69.5 ppm (glycerol carbons), saturated FA at 29.6 ppm (aliphatic carbons), and unsaturated FA at 27.7 ppm (vinyl carbons), consistent with hepatic fat accumulation. In TCDD-treated rats, the dominant 1 H spectral features corresponded to betaine and Pcho (Pcho was also identified in the 31 P spectra from aqueous extracts).
Lipid Metabolism and Transport NMR analysis revealed total hepatic lipid content increased 55% in TCDD-treated mice relative to controls at 72 h (Table 1) . Conversely, no significant change in total hepatic lipid content was detected in rats treated with an equipotent dose of TCDD (Boverhof et al., 2006a , Table 2 ). This suggests that FA accumulation in mice may be partially attributable to increases in hepatic TAG. Rat TAG levels were also elevated, but to a lesser extent, with a~50% increase at 72-120 h and only 20% by 168 h. Polyunsaturated n6-FA content was also induced in both species but was more pronounced in mice. Levels of n6-FA were sustained 45% higher in treated mice, whereas the effect in rats was transient (Tables 1 and 2 ). Cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane, was also reduced in both species (Table 1) . Lipid metabolism and transport gene expression (Boverhof et al., 2006a; Dere et al., 2011a) were examined to associate differential expression to changes in hepatic lipid and FA composition (Tables 3 and 4) . qRT-PCR was also used to further investigate selected genes of interest (guided by the metabolite analysis). Because metabolite analysis was conducted at 72-168 h post TCDD exposure, differential gene expression was examined at 24, 72, and 168 h. Genes associated with FA transport and metabolism as well as glycerophospholipid pathways showed robust differential expression.
GC-MS analysis (Kopec et al., 2010 ; Fig. 2 and Supplementary table S6) identified 16 FAs altered in the mouse but only seven in the rat. Mouse changes included TCDDdependent decreases in long-chain (>16 carbon) saturated fatty acids (SFA), accompanied by decreased expression of FA synthase, and elongases 3 and 6 (Fasn, Elovl3, and Elovl6; Table 3 ). Monounsaturated fatty acid (MUFA) and polyunsaturated fatty acid (PUFA) levels were elevated, consistent with Elovl5 and stearoyl-CoA desaturase 2 (Scd2) induction. TCDD-induced hepatic MUFA and PUFA levels were observed in both mouse and rat, although the effects were more pronounced in mice. For example, 20:1n9 levels were induced 6.5-fold in mice but only twofold in rats at 168 h.
Hepatic lipid flux is mediated by the import, de novo synthesis, intracellular trafficking, packaging, and export processes. Gene expression analysis identified alterations in lipid transport and metabolism contributing to hepatic fat accumulation in mice. For example, the uptake of lipids packaged in lipoproteins is facilitated by cell surface receptors including Ldlr (mouse: no change, rat: up threefold), Vldlr (mouse: up twofold, rat: no change), Apob48r (mouse: up twofold, rat: no change) and CD36 (mouse: up fourfold, rat: down fourfold).
Genes involved in de novo TAG and FA biosynthesis (Dgat2, Acacb, and Acsl3/4) were downregulated 1.5-to 3-fold in mice. Acly, primarily responsible for cytosolic acetyl-CoA and oxaloacetate production, and Fasn were downregulated approximately threefold by TCDD in both species. These results suggest decreased hepatic de novo FA synthesis, consistent with effects reported in HepG2 cells Ruiz-Aracama et al., 2011) , and implicate lipid uptake as a major contributing factor in TCDD-induced steatosis. Intracellular FA binding proteins (Fabp), responsible for intracellular FA transport, were also differentially expressed in mice and rats. In mice, Fabp12 (23-fold), Fabp4, and Fabp5 were all induced, whereas Fabp2 was suppressed. In contrast, only Fabp2 and Fabp5 were induced (fourfold) in the rat. Lipid packaging and export requires apolipoproteins (Apo) and VLDL synthesis. Apo expression was downregulated in the mouse (approximately twofold for Apoa4, Apol7a, Apol9b, and Apon) and divergently regulated in the rat (Apo4 down approximately fourfold; Apoa1 up twofold). Overall, these changes are consistent with fat accumulation and the histopathologic assessments in mice and rats (Boverhof et al., 2006a) .
Hepatic lipid metabolism also requires lipases to cleave FAs from TAG and phospholipids, which were differentially expressed in both species (Tables 3 and 4 ). In mice, 18 unique lipases, colipases, and phospholipases were differentially expressed (5 suppressed and 13 increased, representing several phospholipase classes including PLA, PLC, and PLD). In contrast, only Lpl and PLC-b3 were repressed twofold in the rat. Noteworthy is the differential expression of lipases Pnpla3, Cel, Lpl, and Pnliprp1 in the mouse, which have been associated with dietary lipid absorption and fatty liver development (Gilham et al., 2007; Hoekstra et al., 2010) . In addition, TCDD elicited the differential expression of FA desaturases and elongases, as well as enzymes involved in b-oxidation, consistent with increases in MUFAs and PUFAs (Fig. 2) . In mice, the elongases (Elovl2/3/6) and the desaturase Fads2 were downregulated twofold to threefold, whereas Elovl5 and Scd2 were induced approximately twofold. Acacb, a regulatory step in FA biosynthesis and b-oxidation, was repressed 1.6-fold. However, several b-oxidation genes were induced in rats (Acaa1 fivefold and Cpt1 threefold) but showed only modest induction in mice (Aldh3b1 twofold and Aldh3b2 1.6-fold), suggesting induction of b-oxidation as previously reported (Lin et al., 2011) .
Cholesterol Metabolism and Bile Acid Synthesis
Genes involved in the biosynthesis and metabolism of cholesterol as well as its conversion to bile acids were evaluated to investigate increased hepatic cholesterol levels in mice in response to TCDD (Tables 1 and 3 ). In general, cholesterol biosynthesis genes were repressed by TCDD, suggesting that elevated levels are due to increased hepatic uptake. Cyp7a1 and Ch25h were downregulated fivefold and upregulated twofold, respectively, in mice. Furthermore, mouse Acyl-CoA oxidase 2 (Acox2) involved in secondary bile acid synthesis as well as b-oxidation was induced 1.6-fold. Meanwhile, bile acid synthesis genes Cyp7a1 and Hsd3b7 were downregulated 10-and 2-fold, respectively, with no change in hepatic cholesterol levels in rats (Tables 2 and 4) .
Glycerophospholipid Metabolism
TCDD elicited species-specific effects on glycerophospholipid metabolism, which included changes in hepatic 46 FORGACS ET AL. PtdS, PtdE, SM, cardiolipin, dihydroxyacetone phosphate (DHAP), glycerol phosphocholine (GPC), Pcho, and betaine levels. In rats, hepatic Pcho, a choline metabolite, and PtdC precursor were induced greater than threefold, whereas betaine (oxidative metabolite) levels decreased twofold (Table 2) . Betaine-homocysteine methyltransferase (Bhmt), involved in betaine to sarcosine metabolism, increased twofold in rats but was unchanged by TCDD in mice (Table  4) . Consistent with the increased Pcho levels in rats, choline kinase (Chk) was induced twofold to threefold. Furthermore, rat SM and PtdS levels decreased, and SM phosphodiesterase 3 (Smpd3), which converts SM into Pcho and ceramide, was repressed. However, sphingosine kinase 1 (Sphk1; producing sphingosine-1-phosphate, used for biosynthesis of phosphoethanolamine) was induced twofold, and the SM/ Pcho ratio was reduced~75% in the rat (Fig. 3) . In contrast, SM and Pcho levels as well as the SM/Pcho ratio did not change in mice (Table 1, Fig. 3 ), though betaine levels decreased transiently at 72 h and recovered to control levels by 120 h. Both Chk and choline dehydrogenase (Chdh) were upregulated in the mouse. Decreases in specific phospholipid species were observed, with TCDD-elicited reduction of hepatic PtdE in mice accompanied by the differential expression of ethanolamine kinase (Etnk) and choline phosphotransferase (Chpt). Furthermore, reduced levels of GPC in mice were accompanied by a 1.6-fold decrease in phospholipase Pnpla7, responsible for PtdC metabolism to GPC, and a twofold induction of Lpcat2, which converts 1-acylglycero-3-phosphocholine to PtdC. No such effects on GPC were detected in rats.
Glycolysis and Gluconeogenesis
Mouse-specific decreases in DHAP, glucose-6-phosphate (G6P), and a 30% reduction in lactate at 72 h (Table 1) indicate glycolytic and gluconeogenic pathway perturbations, suggesting a link to TAG synthesis. In mice, TCDD repressed G6pc expression 2.7-fold, Gck 1.6-fold, and Pklr threefold, whereas Pkm2 was induced twofold. The mouse-specific decrease in DHAP and lactate can be represented as a~30% decrease in the lactate/pyruvate ratio (Fig. 4) . While the glycerol-3-phosphate (G3P)/DHAP ratio was unaffected (Fig. 5) , despite decreased expression of glycerol phosphate dehydrogenase 2 (Gpd2; interconversion of DHAP and G3P by the inner mitochondrial membrane bound FAD-linked dehydrogenase; Table 3 ). High activity of cytosolic glycerol phosphate dehydrogenase (an NAD-linked dehydrogenase) facilitates G3P production and is consistent with decreases in the lactate/pyruvate ratio in mice, as the lactate dehydrogenase reaction affects the cytosolic redox potential (NAD þ /NADH ratio). Hepatic lactate decreased by 30% at 72 h, whereas lactate dehydrogenase D (Ldhd) expression was induced 1.7-fold at 168 h. Decreased DHAP levels with no changes in the G3P/DHAP ratio suggest rapid G3P utilization, consistent with hepatic TAG accumulation. In rats, no TCDD-dependent changes were detected in the lactate/pyruvate or G3P/DHAP ratios (Figs. 4 and 5) . However, Pck1, a key regulator of gluconeogenesis, was repressed fourfold as was Fbp1 twofold. Pdh and Pdk, involved in the metabolism of pyruvate to acetyl-CoA, were also downregulated by TCDD in rats only. Of unknown significance is the 112-fold induction of Aldh3a1 in rats, involved in the interconversion of acetaldehyde and acetate. Note. All data were retrieved from the data set published by Dere et al. (2011a) unless indicated otherwise. Gene expression evaluated by qRT-PCR in the current study.
b
Maximum temporal fold change across the experiment with P1(t) > 0.9, at time point indicated in bold.
c
Where jfold changej > 1.5 and P1(t) > 0.9, bold indicates maximum fold change.
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DISCUSSION
Metabolomic and gene expression data integration identified species-specific and -conserved pathways affected by TCDD (Fig.  6) . These results not only confirmed mouse-specific hepatic lipid accumulation but also identified rat-specific choline metabolism perturbations. Qualitative and quantitative changes in specific metabolites were mapped to differential gene expression, providing further evidence of species-specific AhR-mediated effects.
GC-MS confirmed alterations in the levels of 14 of 16 evaluated FAs in mice, consistent with the 22% increased uptake of serum FAs in mice (Boverhof et al., 2005 (Boverhof et al., , 2006a Lee et al., 2010; Sato et al., 2008) . In contrast, only seven FAs were modestly affected in rats. These results are consistent with the mouse-specific hepatic fat accumulation (Boverhof et al., 2006a) and were associated with the differential expression of specific FA metabolism and transport genes. For example, fatty accumulation was associated with the differential expression of nearly 20 lipases and lipoprotein receptors in mice, namely lipases Pnpla3, Pnpla8, Cel, Lpl, and Pnliprp1 (Boverhof et al., 2006a; Gilham et al., 2007; Hoekstra et al., 2010) . Cel and pancreatic lipase cooperate to mediate dietary fat absorption (Gilham et al., 2007) , which may partially explain the twofold increase in the essential dietary linoleic (18:2n6) and Where jfold changej > 1.5 and P1(t) > 0.9, bold indicates maximum fold change.
COMPARATIVE METABOLOMIC AND GENOMIC ANALYSES 49 a-linolenic (18:3n3) acids suggesting that in addition to peripheral fat mobilization, dietary sources also contribute to hepatic fat accumulation (Cimafranca et al., 2004) . Increased phospholipase gene expression would induce cleavage of headgroups from phospholipids, providing additional choline, ethanolamine, inositol, and serine. Phospholipase A2 isoforms were also induced, which could contribute to arachidonic acid signaling pathways and proinflammatory signaling consistent with immune cell infiltration in mice (Boverhof et al., 2006a) . Collectively, differential gene expression associated with lipid transport and FA mobilization, suggests that TCDD-elicited steatosis is due to FA uptake. The induction of cell surface receptors Vldlr, Apob48r, and Cd36 in mice is also consistent with hepatic FA accumulation. Cd36 also facilitates FA uptake and was induced in mice but repressed in rats. Cd36 is AhR regulated, with null mice resistant to TCDD-induced steatosis (Lee et al., 2010) . The divergent AhR regulation of CD36 may also play a role in TCDD-elicited fatty liver. Although fat accumulation could be due to de novo lipogenesis, Acly, the primary enzyme responsible for cytosolic TCDD-induced b-oxidation genes in rats, including Acaa1 and Cpt1a. TCDD-induced b-oxidation in rats, but not mice, is consistent with the species-specific development of fatty liver.
Fabps (e.g., Fabp12 induced 23.5-fold) were also induced in mice, whereas only Fabp5 was induced in rats. As the most abundant cytosolic protein in liver cells, Fabps facilitate FA uptake and intracellular trafficking and have been associated with metabolic syndrome and obesity (Atshaves et al., 2010; Storch and Thumser, 2010) . Dramatic increases in Fabps may contribute to the development of fatty liver and subsequent progression to metabolic syndrome in response to TCDD (Atshaves et al., 2010) . Overall, these species-specific gene expression effects are consistent with mouse-specific accumulation of hepatic lipids.
Increased hepatic FA levels likely contributed to the threefold increase in TAG levels. Decreases in hepatic lactate and the lactate/pyruvate ratio suggest G3PDH is shifted toward G3P production to support TAG biosynthesis. This would upset the cytosolic redox potential (NAD þ /NADH balance) and be compensated by Ldhd induction and a decrease in the lactate/pyruvate ratio. Despite the observed metabolite changes and threefold increase in hepatic TAG levels in mice, Ppap2a, the rate-limiting enzyme in TAG biosynthesis, did not change (data not shown), although its activity can be induced by FAs (Brindley, 1985) . In addition, Dgat2, which is also involved in de novo TAG biosynthesis, was repressed 1.5-fold. Further studies are required to elucidate the pathways or mechanisms associated with hepatic TAG increase by TCDD.
Elovl5 elongates dietary 18:3n3 and 18:2n6 to produce n3-and n6-FAs, respectively, in conjunction with desaturases and other elongases (Guillou et al., 2010) . The twofold induction of Elovl5 is consistent with increased n3-and n6-FAs including a twofold increase in Elovl5 substrates (18:3n3, 18:2n6, and 20:5n3) and threefold to fourfold increase in 20:3n3, 20:2n6, and 22:5n3 products (Guillou et al., 2010) in mice. Elovl5 was induced twofold in the rat, as were its products 20:3n3 and 20:2n6. Repression of mouse Elovl3 and Elovl6 may partially explain the subtle decreases in longer chain saturated FAs (22:0 and 24:0) . No changes in Elovl3, Elovl6, or SFAs were observed in rats. Similar to n3-and n6-FAs, n9-FA levels were also induced in both species. n9-FA biosynthesis requires the rate-limiting stearoyl-CoA desaturase 1 (Scd1), which was unchanged (data not shown) (Angrish et al., 2011) , but Scd2, which is expressed during development (Miyazaki et al., 2005) , was induced 1.5-fold in our model and may explain the 18:1n9 increases (Angrish et al., 2011) .
Cardiolipin (CL), a phospholipid almost exclusive to the inner mitochondrial membrane, was reduced in both species. CL stabilizes electron transport chain (ETC) complexes involved in oxidative phosphorylation and energy production. It is predominantly composed of linoleic acid (18:2n6) side chains (Chicco and Sparagna, 2007; Houtkooper and Vaz, 2008) . Altered CL content and composition have been associated with fatty liver and diabetes (Petrosillo et al., 2007) as well as ETC dysregulation (Houtkooper and Vaz, 2008) . Reduced CL levels may partially explain TCDDmediated mitochondrial toxicity characterized by reactive oxygen species production, lipid peroxidation, decreased ATP levels, and altered ETC enzyme expression and activity (Forgacs et al., 2010; Hagopian et al., 2010; Houtkooper and Vaz, 2008; Stohs, 1990) .
TCDD also disrupted hepatic glycolysis and gluconeogenesis. Mice exhibited a reduced lactate/pyruvate ratio (Fig. 4) , consistent with Ldh induction in favor of pyruvate. The repression of pyruvate kinases Pklr and induction of Pkm2 may further increase pyruvate production by Ldh in response to cytosolic redox potential changes due to increased G3P production by cytosolic G3P dehydrogenase in support of TAG biosynthesis. Furthermore, lactate and pyruvate may be used as substrates for G3P synthesis via gluconeogenesis. In contrast, the lactate/pyruvate ratio was not affected in rats, although Pdha1, Pdk2, Pck1, Fbp1, and Pfkfb1 were downregulated twofold to fourfold, suggesting that TCDD inhibited pyruvate utilization for energy (via the TCA cycle) or its use as a substrate for gluconeogenesis. FA synthesis was also repressed in rats, whereas FA b-oxidation was induced, in agreement with previous metabolomic reports (Lu et al., 2010) . This includes the downregulation of Acly and Fasn and the induction Acaa1 and Cpt1a. Decreased Acac activity has been previously reported in TCDD-treated rats (Lakshman et al., 1989) . Collectively, gluconeogenesis and FA biosynthesis are suppressed, whereas glycolysis and b-oxidation may be induced in treated rats. Rat-specific hepatic responses included alterations in choline metabolism. Betaine, a choline metabolite, was reduced~60% consistent with a twofold increase in betaine-homocysteine methyltransferase (Bhmt) expression. Bhmt induction in alcohol-induced fatty liver is protective against endoplasmic reticulum stress and liver injury (Shinohara et al., 2010) . Moreover, increases in Pcho levels and choline kinase induction (Chka/b) are consistent with enzyme level, and activity increases induced by polycyclic aromatic hydrocarbons in rats (Ishidate et al., 1982) . Consequently, TCDD may increase choline use via Pcho and betaine biosynthesis in rats, a novel finding of this study. Betaine can be metabolized to sarcosine and used as a methyl donor in support of Bhmt activity. No sustained changes in betaine, Pcho, SM, or Bhmt were observed in mice. Rat-specific induction of choline metabolism may protect against hepatic fat accumulation as A B FIG. 6 . Metabolic pathways illustrating TCDD-elicited changes in the mouse (A) and rat (B). Changes in metabolite levels measured by NMR are highlighted in boxes. Gene names (over arrows) were evaluated using whole-genome microarrays. Metabolites and genes affected by TCDD are highlighted in red (upregulated) and green (downregulated). Other genes and metabolites that are involved in the pathway but unaffected by TCDD are shown in gray. Posttranslational modifications that may alter enzyme activity were not assessed but may explain some changes in metabolite levels.
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choline-deficiency induces fatty liver in rodents, characterized by increased FA uptake and gene expression associated with FA uptake as well as inhibition of TAG biosynthesis and secretion (Rinella et al., 2008) . Divergent regulation of choline metabolism may be another contributing factor in TCDDelicited species-specific hepatic fat accumulation.
In summary, TCDD elicits species-specific metabolic disruption that can be associated with species-specific gene expression changes. Specific changes in metabolites and differential gene expression could be associated with steatosis in the mouse and altered choline metabolism in rats. However, complementary enzyme activity assessments are required to fully elucidate the pathways and/or mechanisms responsible for many of the metabolite changes. Moreover, dose-response studies are required to identify additional lipid and aqueous metabolite changes associated with TCDD toxicity and to determine potential human risks. Nevertheless, these results provide additional compelling evidence that despite the conservation of AhR structure and function, differential gene expression is not conserved between species and likely contributes to species-specific responses and differences in sensitivity to TCDD (Boverhof et al., 2006a; Dere et al., 2011a,b,c; Silkworth et al., 2005; Sun et al., 2004; Sutter et al., 2010) . Further studies are required to determine the relevance of these effects in humans.
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